Therapeutic role of fluconazole in immunocompetent patients with pulmonary cryptococcosis: A case report
Abstract
The present investigation examines the potential for customized treatment of pulmonary cryptococcosis using fluconazole in an immunocompetent individual. Therapeutic drug monitoring (TDM) was utilized throughout treatment to assess fluconazole levels. Research indicated that the MIC90 for cryptococcus in China is around 8 mg/L. We evaluated the area under the curve (AUC) relative to the minimal inhibitory concentration (MIC), focusing on the AUC from 0 to 24 h (AUC0-24 h/MIC). Fluconazole's dosage was adjusted according to pharmacokinetics/pharmacodynamics (PK/PD) principles to enhance therapeutic efficacy. Post-treatment evaluation showed marked improvement in the patient's condition, with lesions exhibiting partial absorption.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.